Neosporin expands with lip care line
NEW YORK Neosporin, a Johnson & Johnson Consumer Cos. brand, is diving into the dry lip segment with the launch of its new Neosporin Lip Health daily hydration therapy and Neosporin Lip Health overnight renewal therapy.
The new products, which are shipping now, will join a portfolio of existing Neosporin products, including Neosporin LT Lip Treatment for the treatment of cold sores and severely dry chapped lips.
The new lip products are clinically shown to restore visibly healthier lips in three days, according to the company.
Neosporin Lip Health daily hydration therapy contains SPF 20 to protect lips from sunburn and both formulas feature a patented combination of lipids and antioxidants to soften and smooth lips. Peptides, vitamins and emollients also help to nourish and strengthen lips over time.
Both products have a suggested retail price of $4.99.
Matrixx seeks to increase brand awareness with more advertising
SCOTTSDALE, Ariz. Matrixx plans to step up its advertising this cough-cold season, converting one-time nasal swab users into purchasers of one of several Zicam oral remedies, Bill Hemelt, acting president and COO, told shareholders during the company’s annual meeting held Wednesday.
“The landscape for the company has changed dramatically as a result of the June 16 [Food and Drug Administration] warning letter,” Hemelt said, referencing the agency’s written concerns that Matrixx’ nasal Zicam products could be associated with an increase in anosmia (the loss of the sense of smell).
Matrixx voluntarily pulled those products off the shelf following that warning letter, though Hemelt noted that so far 10 federal judges had dismissed similar claims prior to the FDA letter.
Accompanying the increased advertising support, Matrixx also plans on implementing a sizeable retail promotional support. “We worked with our retail partners to modify [cough/cold sets] to feature oral Zicam products,” Hemelt said. Hemelt thanked the company’s retail partners for their collective support.
NAD questions dietary supplement’s safety; submits concerns to FTC, FDA
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Wednesday referred advertising from Metabolic Research around its Stemulite dietary supplement to the Federal Trade Commission and Food and Drug Administration for further review, following the company’s decision not to participate in an NAD review of advertising for the product.
As a part of its ongoing monitoring program and in conjunction with an initiative with the Council for Responsible Nutrition to expand the review of advertising claims for dietary supplements, NAD – the advertising industry’s self-regulatory forum – requested that the company provide supporting evidence for advertising claims including,“People who take Stemulite experience deep REM sleep, increased muscle gain and endurance, increased weight loss and fat loss and increased wellness and energy.”
As part of its review, NAD also expressed concerned about several testimonials on the Stemulite Web site.
The advertiser contacted NAD, and despite requesting and being given an extension of time within which to file its response, failed to do so. The advertiser represented to NAD that it would be conducting a study in the future and would participate after the completion of the study.
NAD noted that it is a well-settled principle of advertising law that an advertiser must possess adequate substantiation before it publishes advertising claims. NAD’s procedures provide that if an advertiser does not participate in the process, NAD may refer the advertising at issue to the appropriate government agency for further review.
NAD was “disappointed that the advertiser did not participate in the NAD inquiry, particularly in light of the health and weight-loss claims being made.” Based on the advertiser’s failure to participate, NAD will refer this matter to the FTC and FDA for possible law enforcement action.